FDA Hits Snooze Button on 1970s Hormone Drug Review
Published Date: 6/26/2026
Notice
Summary
The FDA is giving itself 90 more days—until September 24, 2026—to finish reviewing important feedback about certain estrogen-androgen combo drugs like Syntest tablets. This means the final decisions about these drugs’ approval are on hold a bit longer, affecting drug makers and patients waiting for updates. No extra costs are mentioned, just more time to get it right!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
FDA delays enforcement 90 days
The FDA is giving itself 90 more days — moving the effective date from June 26, 2026, to September 24, 2026 — to consider comments on estrogen-androgen fixed-combination drug products (including those discussed for Syntest tablets). That means the FDA will not implement the May 27, 2026, final resolution until September 24, 2026.
Unapproved products become unlawful
The May 27, 2026, final resolution found that estrogen-androgen fixed-combination drug products lack substantial evidence of effectiveness for treating moderate to severe vasomotor symptoms in patients not improved by estrogen alone, and shipment in interstate commerce of any identified or identical, related, or similar product that is not subject to an approved NDA or ANDA will be unlawful as of the notice's effective date. With the extension, that unlawfulness is scheduled to take effect on September 24, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19921, Determination That SULFADIAZINE (Sulfadiazine) Tablet, 500 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that the 500 mg sulfadiazine tablet wasn’t taken off the market because it was unsafe or didn’t work. This means generic drug makers can now apply to sell their versions, as long as they meet all the rules. Patients and pharmacies could see more affordable options soon, with no safety worries holding things back.
2026-19850, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Submission of Petitions: Food Additive, Color Additive (Including Labeling), Submission of Information to a Master File in Support of Petitions; and Electronic Submission Using Food and Drug Administration Form 3503
The FDA is asking for public feedback on how it collects info about food and color additives, including their labels and safety petitions. This affects companies that want to add or change ingredients in food and how they submit their paperwork electronically. Comments are due by October 29, 2026, and the process helps keep food safe without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-12931, Formations of, Acquisitions by, and Mergers of Bank Holding Companies
Bank companies want to join forces or buy each other, and the Federal Reserve is checking their plans to keep things fair and safe. If you care, you’ve got until July 27, 2026, to share your thoughts. These moves could shake up local banks and might affect how money flows in your community.
Next: 2026-12936, Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company
Some folks want to buy shares in banks or bank companies, and the Federal Reserve is checking their applications to make sure everything’s fair and safe. If you want to share your thoughts, you’ve got until July 13, 2026, to speak up! This process helps keep banks strong and protects everyone’s money.